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Abstract: The interaction between cucuribit[7]uril (Q[7]) and Adefovir (ADV) has 
been studied in aqueous solution by 1H NMR spectroscopy, electronic absorption 
spectroscopy, Isothermal Titration Calorimetry and mass spectrometry. The results 
revealed that an inclusion complex was formed via encapsulation of the purine rings 
of the guest ADV, while the phosphonomethoxyethyl group was prevented from 
entering the cavity. ITC data revealed that the formation of this 1:1 inclusion complex 
is mainly driven by favourable enthalpy changes. Studies investigating the release of 
ADV from the inclusion complex revealed enhanced rates under acidic conditions, 
although the rates were slower than observed for the free guest under the same 
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conditions. Thermal stability studies indicated that the included form of ADV was 




Adefovir (ADV) was originally of interest in the 1990s for the treatment for HIV, but 
complications with dosage size versus kidney problems led to its withdrawal by the 
FDA. [1] However, the use of lower dosages proved fruitful for the treatment of 
hepatitis B, and in the early 2000s, Adefovir was approved for use. [2] The medicinal 
potential of compounds such as Adefovir can be broadened and/or improved if 
delivery to specific targets in the body is achieved without degradation. With this in 
mind, we are interested in the host-guest properties of cucurbit[n]urils, Q[n]s, which 
given their enhanced solubility, recognition properties, ability to cross cell membranes 
and favorable toxicity profiles are attractive as containers/scaffolds for drug delivery. 
[3] This is exemplified by the work of Isaacs et al who have made use of 
cucurbit[7]uril to deliver oxaliplatin to cancer cells, [4] whilst Wang et al reported 
reduced toxicity but preservation of anticancer activity for Q[7] encapsulated 
camptothecin. [5] The host-guest complex formed between Q[7] and oxaliplatin 
demonstrated enhanced antitumour activity (using colorectal cells) versus only 
oxaliplatin, which illustrated the potential for supramolecular chemotherapy. [6] There 
is also potential for such an approach to be employed in the war against 
neurodegenerative diseases, such as Parkinson’s disease. [7] Other complexation 
studies on Q[n]s and multinuclear platinum complexes suggested that Q-based 
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scaffolds can, via encapsulation, provide steric hinderance to drug degradation and 
thus have potential for pharmacological delivery. [8] Other work by Zheng and Wang 
has reported how the presence of Q[7] can improve the in-vitro and in-vivo uptake of 
the dye molecule coumarin-6; [9] coumarin forms a 1:1 inclusion complex with Q[7] 
but a 2:1 complex with Q[8]. [10] Other drugs such as atenolol, glibenclamide, 
memantine and paracetamol can be stabilized in the solid state by forming inclusion 
complexes with Q[7], [11] whilst increased stability (2 to 3x versus similar sized 
β-cyclodextrin) constants are observed for the anaesthetics procaine, tetracaine, 
procainamide, dibucaine and prilocaine in aqueous solution. [12] The histamine 
H2-receptor antagonist rantidine has also exhibited increased stability in acidic 
aqueous solution in the presence of Q[7], [13] as did the antituberculosis drugs 
pyrazinamide and isoniazid. [14] Furthermore, the problematic cardiotoxicity of the 
antituberculosis drug clofazimine can be almost completely eliminated by 
complexation with Q[7]. [15] It is against this background that we now report our 
findings on the interaction of Q[7] with Adefovir (ADV) (see Scheme 1). Results are 
compared against out earlier study of the pro-virucide Adefovir bis(L-leucine 
propyl)ester (PMEA-Leu) – see scheme 1, left. [16] 
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Scheme 1. Schematic molecular structures of ADV, PMEA-Leu and Q[7]. 
 
2 Results and Discussion 
2.1 NMR spectroscopy 
In order to investigate the complexation of Q[7] with ADV in solution,1H NMR 
spectroscopic titration experiments were first performed by adding increasing 
amounts of Q[7] into the solution of ADV in D2O. A slight up-field shift of the signals 
of the protons of the purine ring was observed when Q[7] was added, and these 
up-field shifts of the purine ring proton signals can be classified into Ha and Hb. The 
resonance of the protons Ha, and Hb experience upfield shifts of 0.59 ppm and 0.73 
ppm, while the resonances of protons Hc, and Hd associated with the alkyl chain 
exhibited up-field shifts of 0.55 ppm and 0.39 ppm, respectively. By contrast, the 
resonance of the proton He experiences a downfield shift of 0.48 ppm when the ratio 
of ADV/Q[7] reaches 1:1.57. These shift observations indicate that the purine rings 
were all accommodated within the cavity of Q[7], whereas the 
phosphonomethoxyethyl was prevented from entering the cavity. These results differ 
from our early observations for the pro-virucide Adefovir bis(L-leucine propyl)ester 
(PMEA-Leu), [16] where the two ends of the branches (ie. the leucine propyl groups) 
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of PMEA-Leu (see scheme 1) were included in the Q[7] cavity. Thus, in the case of 
the interaction between PMEA-Leu and Q[7], the situation is best described as a 




Figure 1. 1H NMR spectra of ADV (A), ADV and Q[7] in the ratio of 0.30 (B), 0.36 (C), 0.47(D), 
0.90 (E), 1.0 (F), 1.08 (G), 1.38 (H), 1.57 (I) and Q[7] (K) in D2O 
 
UV absorption spectroscopy  
The supramolecular interactions of the Q[7]/ADV host-guest inclusion complex were 
then further investigated by the use of UV spectroscopy. As shown in Figure 2A and B, 
the drug ADV exhibited a maximum UV absorption at 261 nm in aqueous media, 
whilst Q[7] exhibited no absorbance in the range ≥210 nm. On addition of increasing 
amounts of the host Q[7] to ADV at a fixed ADV concentration of 4.0×10-5 M, the 
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absorption spectra of the ADV became weaker. These observations indicate that the 
interaction between Q[7] and ADV has occurred. Furthermore, in Figure 2C the 




Figure 2. UV absorption of ADV (4.0×10-5mol·L-1) upon the addition of increasing amounts (0, 
0.1, 0.2...2.6, 2.8 equiv) of Q[7] (A), the concentrations and the corresponding ∆A vs. NiQ[7]/NADV 
curve (B) and the ∆A~ NQ[7]/NQ[7]+NADV curves (C). 
  
Isothermal Titration Calorimetry 
To study the thermodynamics parameter of the complexation between ADV and Q[7], 
we conducted ITC experiments at 298.15 K in pure water. The titration graphs and the 
thermodynamic parameters data are shown in Figure 3 and Table 1 respectively, and 
the experimental results revealed a Ka value of (4.25±0.22)×104 M-1. This Ka value is 
indicative of effective binding between ADV and Q[7]. Furthermore, the negative 
enthalpy variation, ∆H°= (-29.05±0.13) kJ·mol-1 and the negative entropy variation, 
T∆S° = (-2.41±0.26) kJ·mol-1, indicate that the formation of the inclusion complex 
between ADV and Q[7] is mainly driven by favourable enthalpy changes, 
accompanied by small negative (unfavourable) entropy changes. 
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Figure 3 Isothermal titration calorimetry profiles of Q[7] with ADV in aqueous solution at 298.15 
K. Nano ITC data for 30 sequential injections of ADV solution into TMeQ[7] solution (top). 
Apparent reaction heat obtained from integration of the calorimetric traces (bottom). 
 
 
Table 1. The thermodynamic parameters of ADV/Q[7]. 
 
Complex n Ka (M −1) ΔH° (kJ mol–1) TΔS° (kJ mol–1) 
ADV/Q[7] 1.07 (4.25±0.22)×104 (-29.05±0.13) (-2.41±0.26) 
 
MALDI-TOF mass spectrometry 
  Analysis of the inclusion complex by MALDI-TOF mass spectrometry revealed 
(see Figure 4) an intense signal at m/z=1436.01, which corresponds to ADV/Q[7] 
(calculated 1435.53), thereby providing direct support for the formation of the 1:1 
stoichiometry for the host-guest inclusion complex ADV/Q[7]. 
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Figure 4. MALDI-TOF mass spectrum of the complex ADV/Q[7]. 
 
Controlled release behaviour 
To understand the controlled release performance of this inclusion complex, the ADV 
release from inclusion complex ADV/Q[7] was investigated in water at 37 ℃ 
(Figure 5). The ADV and ADV/Q[7] are released, via the use of a dialysis bag (for 
full details see experimental section), on an orbital oscillator and the solution curve 
for drug release is obtained based on the solution absorption of the drug at different 
times (Figure 5). When the solution pH was kept at 6.8 using a NaH2PO4/ Na2HPO4 
buffer, the ADV was totally released after 25 min. Whereas, in the case of the 
inclusion complex ADV/Q[7], the ADV was released from the Q[7] over 145 min, 
which indicated that the release time of ADV from the inclusion complex was 
longer than that in the case of the free guest. The released amounts of ADV and 
ADV/Q[7] were respectively 57.8% and 58.2%. When the pH was about 1.2, the 
ADV was totally released after 35 min., whilst ADV was released from Q[7] showed 
over 85 min.; the released amounts of ADV and ADV/Q[7] were 48.7% and 45.1% 
respectively (Figure 6). In short, these results indicate that the pH of the solvent 
medium can act as a trigger for release, ie for the free drug, the released amounts 
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of ADV at pH 6.8 was more than at pH 1.2, and similarly for the ADV/Q[7] complex, 
at pH 6.8, both the release time and the amounts of drug was more than at pH 1.2.   
  
Figure 5. The UV absorption changes in the release for free guest ADV at pH = 6.8 (a, b), 
inclusion complex ADV/Q[7] at pH = 6.8 (c, d), free guest ADV at pH = 1.2 (e, f) and inclusion 
complex ADV/Q[7] at pH = 1.2 (g, h) in water. 
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Figure 6. The release curves obtained for free guest ADV and inclusion complex ADV/Q[7] at pH 
= 6.8 (a), and pH = 1.2 (b) in water. 
 
Thermal stability analysis 
From the DTA spectra (Figure 6), it is also evident that ADV and Q[7] interacted with 
each other. Analysis of the thermal stabilities is via the use of differential scanning 
calorimetry (DSC) and thermogravimetry (TG). As shown in Figure 7, Q[7] has a 
broad endothermic peak at 402.1°C typical of an amorphous material, and crystalline 
ADV has a sharp melting endothermic peak at 306.1°C. Whilst for the ADV/Q[7] 
inclusion complex a clear melting point endothermic peak is observed at 395.1°C. The 
results are consistent with the formation of a new material with improved thermal 
stability of ADV. 
 
Figure 7. DSC spectra of ADV, Q[7] and inclusion complex ADV/Q[7]. 
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Conclusion  
We have investigated the interaction between cucuribit[7]uril (Q[7]) and the hepatitis 
B drug Adefovir by a variety of techniques such as 1H NMR spectroscopy, electronic 
absorption spectroscopy, Isothermal Titration Calorimetry and mass spectrometry. At 
an ADV:Q[7] ratio in excess of 1:1, NMR observations indicate that the guest purine 
rings are encapsulated by the Q[7], whilst the phosphonomethoxyethyl was prevented 
from entering the cavity. ITC results indicate that the formation of the 1:1 inclusion 
complex is mainly driven by favourable enthalpy changes. The controlled release of 
ADV from this inclusion complex was investigated in water at 37 oC at pHs 6.8 and 
1.2 using an orbital oscillator. The release was faster under more acidic conditions, 
though in both cases the process was slower than that observed for the free guest. 
Analysis of the starting materials and the inclusion complex by differential scanning 
calorimetry (DSC) indicated that the new inclusion compound afforded a form of 
ADV that was more thermally stable than the free guest. These studies suggest there is 
potential to use Q[7] to enhance the stability of ADV-type molecules and to control 
the release of such drug molecules by manipulation of the pH employed. Further 
studies are on-going in our laboratory to investigate the ability of Q[7] to act as a 
scaffold for other drug molecules. 
 
Experimental 
Materials and apparatus 
The host Q[7] was prepared according to the literature method. [16] Adefovir (ADV) 
was obtained from Aldrich and was used without further purification. All other 
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reagents were of analytical grade and were used as received. Double-distilled water 
was used for all experiments. 
Preparation of ADV/Q[7]: The required amounts of Q[7] and ADV were respectively 
weighed according to the ratio of NQ[7]:NADV = 1:1, and then dissolved in distilled 
water and stirred for 30 min. The solvent was then evaporated to afford the 1:1 
inclusion compound ADV/Q[7]. 
 
1H NMR spectroscopy 
To study the host-guest complexation of Q[7] and ADV, all the 1H NMR spectra, 
including those for the titration experiments, were recorded at 298.15 K on a JEOL 
JNM-ECZ400S 400 MHz NMR spectrometer (JEOL) in D2O. D2O was used as a 
field-frequency lock, and the observed chemical shifts are reported in parts per 
million (ppm). The concentration of Q[7] employed in the NMR experiments was1.0 
× 10−4 mol/L. 
UV–vis Absorption measurements 
UV-vis absorption spectra of the host-guest complexes were recorded using an Agilent 
8453 spectrophotometer at room temperature. The aqueous solution of ADV was 
prepared with a concentration of 1.00 × 10-3 mol/L. An aqueous solution of Q[7] was 
prepared with a concentration of 1.00 × 10-3 mol/L for absorption spectra 
determination. The UV-vis absorption experiments were performed as follows: 400 
μL of a 1.00 × 10-3 mol/L stock solution of adefovir and various amounts of an 
aqueous 1.0 × 10−3mol/L Q[7] solution were transferred into a 10 mL volumetric flask, 
and then the volumetric flask was filled to the final volume with distilled water. The 
pH was adjusted to pH =7 with sodium phosphate. Samples of these solutions were 
combined to give solutions with an ADV:Q[7] ratio of 0, 0.1, 0.2, 0.3, 0.4, 0.5...... and 
2.8. The formation constants of the ADV@Q[7] complexes (K) (1:1) were calculated 
according to curve fitting method. The Jobs plot method was used to determine the 
inclusion ratio of the substance, NQ[8]:N(Q[7] + ADV) = 0, 0.1, 0.2, 0.3, ..., 1.0. 
 
Isothermal titration calorimetry (ITC) experiments 
Microcalorimetric experiments were conducted using an isothermal titration 
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calorimeter Nano ITC 2G (TA, USA). The amount of heat released was recorded at 
298.15 K. The solution of Q[7] (1.00×10 -4 mol/L) was added to a small amount of 
thermal reaction cell (1.3 mL) and the free solution (1.00×10-3 mol/L) was 
continuously injected into the syringe (250μL ). The dilution heat-corrected reaction 
of the guest solution was determined in a separate experiment. All solutions were 
degassed by sonication prior to the titration experiments. Computer simulations 
(curve fitting) were performed by using the Nano ITC analysis software. 
 
In vitro release studies 
The in vitro drug release behavior of the inclusion compound was investigated on an 
orbital oscillator. The 2.7 mg ADV and 14.3 mg ADV/Q[7] (NADV:NQ[7]=1：1) 
inclusion compound were weighed accurately and then placed on a dialysis bag 
respectively, and next the sample bags were placed in an orbital oscillator containing 
artificial intestinal fluid (pH=6.8 phosphate buffer solution) or artificial gastric juice 
(pH=1.2) hydrochloric acid solution). To this was added an equivalent of hydrochloric 
acid containing 0.09% Na+ ion, which was shaken slowly in a water bath at 37°C. At 
regular time intervals, 1mL of the sample was removed, whilst at the same time 
adding the same volume of the new buffer solution. The absorbance of the sample was 
measured at 260 nm. 
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